

# ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF CAPECITABINE HCL BY USING RP HPLC

NAROTTAM PAL\*, SYED AWAISUDDIN, SHAIK IMRAN, V. SHIRISHA, MAHESH  
Department of Pharmaceutical Analysis and Quality Assurance, Bhaskar Pharmacy College,  
Yenkappally, Moinabad, Hyderabad, Telangana, India

**ABSTRACT :** The objective of the present research work was to develop an innovative, simple, and economic method for estimation of Capecitabine in bulk and dosage form by RP-HPLC. The chromatographic conditions were performed on Symmetry C18, 250 mm x 4.6 mm and 5 $\mu$ m Column, Mobile Phase : 0.01M Phosphate Buffer(P<sup>H</sup> 5.2): Acetonitrile = 45 : 65, flow 1.0 ml/min with Injection Volume 20 $\mu$ l, at detection wavelength 243 nm, run time at 06mins and Retention time was 4.398mins. The analytical method is valid for estimation of Capecitabine over a range of 0-35  $\mu$ g/ml. The results of system suitability test, linearity, precision and accuracy, robustness, specificity, LOD and LOQ and stabilities presented in this report are within the acceptance range. A specific, sensitive, economic method estimation of Capecitabine has been developed based on ICH Guidelines with bulk and dosage forms.

**Key Words:** Capecitabine, HPLC, Method Development, ICH, Validation, Accuracy, Precision.

## I. INTRODUCTION

Capecitabine is a prodrug that is selectively tumour-activated to its cytotoxic moiety, fluorouracil, by thymidine phosphorylase, an enzyme found in higher concentrations in many tumors compared to normal tissues or plasma. Fluorouracil is further metabolized to two active metabolites, 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP), within normal and tumour cells. These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex.

**IUPAC Name** : pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate




Fig-1: Structure of Capecitabine

## II. EXPERIMENTAL

### 2.1 Materials and Methods:

Pharmaceutical grade working standard Capecitabine were obtained from Orchid Pharma from India. All chemicals and reagents were HPLC grade and were purchased from S D Fine-Chem Limited & Loba Chemie Pvt Ltd, Mumbai, India.

### 2.2 Instrumentation:

The analysis was performed using HPLC (Waters-717 series) with PDA detector and data handling system EMPOWER2 software, UV-Visible double beam spectrophotometer (T60-LAB INDIA), analytical balance 0.1mg Sensitivity (SHIMADZU), pH meter (Labindia), ultra sonicator. The column used is Symmetry C18 Column, 250 mm x 4.6 mm and 5 $\mu$ m (as Stationary phase) with the flow rate 1.0ml/min (isocratic).

### 2.3 Sample & Standard Preparation for the Analysis

10 mg of Capecitabine standard was transferred into 10 ml volumetric flask, dissolved & make up to volume with Methanol. Further dilutions was done by transferring 1 ml of the above solution into a 10ml volumetric flask and make up to volume with methanol to get 100ppm concentration. Then, the final concentration was made by transferring 1 ml of the above solution into a 10ml volumetric flask and make up to volume with methanol to get 10ppm concentration. It is scanned in the UV spectrum in the range of 200 to 400nm.

### 2.4 Selection of wavelength

The standard & sample stock solutions were prepared separately by dissolving standard & sample in a solvent in methanol diluting with the same solvent. (After optimization of all conditions) for UV analysis. It is scanned in the UV spectrum in the range of 200 to 400nm. While scanning the Capecitabine solution we observed the maxima at 243 nm.




Fig-2: UV Spectrum for Capecitabine

### 2.5 Method Development

#### 2.5.1 Preparation of Mobile Phase:


450ml of Phosphate buffer (pH 5.2) and 650ml of HPLC Grade Acetone were mixed well and degassed in ultrasonic water bath for 15 minutes. The solution was filtered through 0.45  $\mu$ m filter under vacuum filtration.

#### 2.5.2 Summary of Optimized Chromatographic Conditions:


The Optimum Chromatographic conditions obtained from experiments can be summarized as below:

Table-1: Summary of Optimized Chromatographic Conditions

|                                |   |
|--------------------------------|---|
| Mobile phase                   | 0.01M Phosphate Buffer(P <sup>H</sup> 5.2):<br>Acetonitrile = 45 : 65 |
| Column                         | Waters ODS (C18) RP Column, 250 mm<br>x 4.6 mm. 5 $\mu$ m             |
| Column Temperature             | Ambient   |
| Detection Wavelength           | 243 nm  |
| Flow rate                      | 1.0 ml/ min.  |
| Run time                       | 09 min.   |
| Temperature of Auto<br>sampler | Ambient   |
| Diluent                        | Mobile Phase  |



**Fig-3: Chromatogram for Blank Preparation**



**Fig-4: Chromatogram of Capecitabine in Optimized Condition**

## 2.6 Method validation:

### 2.6.1 Linearity & Range:

Calibration standards at five levels were prepared by appropriately mixed and further diluted standard stock solutions in the concentration ranges from 0-70 $\mu$ g/ml for Capecitabine. Samples in triple injections were made for each prepared concentration. Peak areas were plotted against the corresponding concentration to obtain the linearity graphs. Chromatograms of each solution were recorded.




Fig-5: Calibration Curve of Capecitabine (API)

Table-2: Concentration of Capecitabine

| S. No. | Conc. (µg/ml) | Mean Peak Area |
|--------|---------------|----------------|
| 1      | 0             | 0              |
| 2      | 30            | 433629         |
| 3      | 40            | 565842         |
| 4      | 50            | 689871         |
| 5      | 60            | 799563         |
| 6      | 70            | 949312         |

2.6.2. Accuracy:

To determine the accuracy of the proposed method, recovery studies were carried out by adding different amounts (80%, 100%, and 120%) of pure drug of Capecitabine were taken and added to the pre-analyzed formulation of concentration 50µg/ml. From that percentage recovery values were calculated. The results were shown in table-3.

Table-3: Accuracy Readings

| Sample ID              | Concentration (µg/ml) |              | Peak Area | % Recovery of Pure drug | Statistical Analysis                                      |
|------------------------|-----------------------|--------------|-----------|-------------------------|---|
|                        | Amount Added          | Amount Found |           |                         |   |
| S <sub>1</sub> : 80 %  | 40                    | 39.43539     | 528252    | 98.58849                | Mean= 99.47315%<br>S.D. = 1.102797<br>% R.S.D.=1.108637   |
| S <sub>2</sub> : 80 %  | 40                    | 40.28347     | 539612    | 100.7087                |   |
| S <sub>3</sub> : 80 %  | 40                    | 39.64891     | 531112    | 99.12227                |   |
| S <sub>4</sub> : 100 % | 50                    | 49.34827     | 661035    | 98.69654                | Mean= 99.62055%<br>S.D. = 0.183955<br>% R.S.D.= 0.1865280 |
| S <sub>5</sub> : 100 % | 50                    | 49.20538     | 659121    | 98.41077                |   |

|                        |    |          |        |          |   |
|------------------------|----|----------|--------|----------|---|
| S <sub>6</sub> : 100 % | 50 | 49.37716 | 661422 | 98.75433 | Mean= 99.87567%<br>S.D. = 0.775816<br>% R.S.D.= 0.7767817 |
| S <sub>7</sub> : 120 % | 60 | 59.59732 | 798321 | 99.32887 |   |
| S <sub>8</sub> : 120 % | 60 | 59.72072 | 799974 | 99.53454 |   |
| S <sub>9</sub> : 120 % | 60 | 60.45816 | 809852 | 100.7636 |   |

### 2.6.3. Precision:

#### 2.6.3.1. Repeatability

The precision of each method was ascertained separately from the peak areas & retention times obtained by actual determination of six replicates of a fixed amount of drug, Capecitabine (API). The percent relative standard deviation was calculated for Capecitabine are presented in the Table-4.

**Table-4: Repeatability Readings of Capecitabine**

| HPLC Injection Replicates of Capecitabine | Peak Area      |
|---|----------------|
| Replicate – 1                             | 9677961        |
| Replicate – 2                             | 9739160        |
| Replicate – 3                             | 9673810        |
| Replicate – 4                             | 9649981        |
| Replicate – 5                             | 9606331        |
| Replicate – 6                             | 9616451        |
| <b>Average</b>                            | 9660616        |
| <b>Standard Deviation</b>                 | 48279.61       |
| <b>% RSD</b>                              | <b>0.49975</b> |

#### 2.6.3.2. Intermediate precision:

The intra & inter day variation of the method was carried out & the high values of mean assay & low values of standard deviation & % RSD (% RSD < 2%) within a day & day to day variations for Capecitabine revealed that the proposed method is precise.

**Table-5: Results of Intra-Assay & inter-assay**

| Conc. Of Capecitabine (API) (µg/ml) | Observed Conc. Of Capecitabine (µg/ml) by the proposed method |       |            |       |
|-------------------------------------|---|-------|------------|-------|
|                                     | Intra-Day   |       | Inter-Day  |       |
|                                     | Mean (n=6)  | % RSD | Mean (n=6) | % RSD |
| 40                                  | 49.98   | 0.99  | 41.99      | 1.05  |
| 50                                  | 59.99   | 0.98  | 59.99      | 0.96  |
| 60                                  | 69.98   | 1.02  | 68.98      | 0.95  |

#### 2.6.4. Method Robustness:

Influence of small changes in chromatographic conditions such as change in flow rate ( $\pm 0.1$  ml/min), Wavelength of detection ( $\pm 2$  nm) & organic phase content in mobile phase ( $\pm 5\%$ ) studied to determine the robustness of the method are also in favour of (Table-6, % RSD < 2%) the developed RP-HPLC method for the analysis of Capecitabine (API).

**Table-6: Results of Method Robustness Test**

| Change in parameter              | % RSD |
|----------------------------------|-------|
| Flow (1.1 ml/min)                | 0.08  |
| Flow (0.9 ml/min)                | 0.67  |
| Temperature (27 <sup>0</sup> C)  | 0.75  |
| Temperature (23 <sup>0</sup> C)  | 0.58  |
| Wavelength of Detection (245 nm) | 0.63  |
| Wavelength of detection (241 nm) | 0.82  |

#### 2.6.5. LOD & LOQ:

The detection limit (LOD) and quantitation limit (LOQ) may be expressed as:

$$L.O.D. = 0.33(SD/S).$$

$$L.O.Q. = 0.10(SD/S)$$

Where, SD = Standard deviation of the response

S = Slope of the calibration curve

The Minimum concentration level at which the analyte can be reliable detected (LOD) & quantified (LOQ) were found to be 0.003 & 0.009  $\mu$ g/ml respectively.

#### 2.6.6. System Suitability Parameter

System suitability testing is an integral part of many analytical procedures. The tests are based on the concept that the equipment, electronics, analytical operations and samples to be analyzed constitute an integral system that can be evaluated as such. Following system suitability test parameters were established. The data are shown in Table-7.

**Table-7: Data of System Suitability Parameter**

| S. No | Parameter         | Capecitabine |
|-------|-------------------|--------------|
| 1     | Retention time    | Above 2mins  |
| 2     | Tailing factor    | $T \leq 2$   |
| 3     | Theoretical plate | $N > 2000$   |

#### 2.6.7 Estimation of Capecitabine in Tablet Dosage Form

Twenty tablets were taken and the I.P. method was followed to determine the average weight. Above weighed tablets were finally powdered and triturated well. A quantity of powder equivalent to 10 mg of drug were transferred to 10 ml volumetric flask, and 8 ml of mobile phase was added and solution was sonicated for 15 minutes, there after volume was made up to 10 ml with mobile phase. Then 1ml of the above solution was diluted to 10 ml with HPLC grade methanol. The solution was filtered through a membrane filter (0.45  $\mu$ m) and sonicated to degas. From this stock solution (1.0 ml) was transferred to five different 10 ml volumetric flasks and volume was made up to 10 ml with same solvent system.

**Table-8: Assay of Capecitabine Tablets  
Recovery Data for estimation Capecitabine**

| Brand name of Capecitabine | Labelled amount of Drug (mg) | Mean ( $\pm$ SD) amount (mg) found by the proposed method (n=6) | Assay % ( $\pm$ SD) |
|----------------------------|------------------------------|---|---------------------|
| Xeloda tab                 | 500mg                        | 499.98 ( $\pm$ 0.03)  | 98.86 ( $\pm$ 0.79) |

**Result & Discussion:** The amount of drug in Xeloda tablets was found to be 499.98 ( $\pm$ 0.03) mg/tab for Capecitabine and 99.86 ( $\pm$ 0.79) mg/tab for Capecitabine.

### III. RESULTS

The optimized The chromatographic conditions were performed on Symmetry C18, 250 mm x 4.6 mm and 5 $\mu$ m Column, Mobile Phase : 0.01M Phosphate Buffer(P<sup>H</sup> 5.2): Acetonitrile = 45 : 65 flow 1.0 ml/min with Injection Volume 20 $\mu$ l, at detection wavelength 243 nm, run time at 09 mins and Retention time was 4.398mins.

The results obtained in method validation were :

**Linearity & Range:** The calibration curve showed good linearity in the range of 0-70 $\mu$ g/ml, for Capecitabine (API) with correlation coefficient ( $r^2$ ) of 0.998 (Fig-28). A typical calibration curve has the regression equation of  $y = 13395x - 14892$  for Capecitabine..

**Accuracy:** From the Accuracy Method, we observed that the mean %Recovery of the drug are 100.07 which is within the range of 98-102% and %RSD is within the range  $<2$  i.e. 1.108637%, 0.1865280% and 0.7767817% respectively

**Repeatability:** From the Precision method, we observed that the %RSD 0.49975 which are within the acceptable range as per ICH guidelines.

**LOD & LOQ:** The Minimum concentration level at which the analyte can be reliable detected (LOD) & quantified (LOQ) were found to be 0.003 & 0.009  $\mu$ g/ml respectively..

**Assay:** The amount of drug in Xeloda tablets was found to be 499.98 ( $\pm$ 0.03) mg/tab for Capecitabine and 99.86 ( $\pm$ 0.79) mg/tab for Capecitabine.

### IV. DISCUSSION

To develop a precise, linear, specific RP-HPLC method for analysis of Capecitabine, different chromatographic conditions were applied & the results observed were compared with the methods available in literatures.

**Pani Kumar AD et al(2011):** A simple, rapid accurate and stability indicating RP-HPLC method was developed for the determination of Capecitabine in pure and tablet dosage form. The method showed a linear response for concentrations in the range of 70-120  $\mu$ g/ml using 0.05M phosphate buffer (p H 3.0  $\pm$  0.05) buffer and acetonitrile (50:50 % w/v) as the mobile phase with detection at 240 nm and a flow rate of 1 mL/min and retention time 4.108 min. The method was statistically validated for accuracy, precision, linearity, ruggedness, robustness, forced degradation, solution stability and selectivity.

### V. CONCLUSION

A sensitive & selective stability indicting RP-HPLC method has been developed & validated for the analysis of Capecitabine API. Based on peak purity results, obtained from the analysis of samples using described method, it can be concluded that the absence of co-eluting peak along with the main peak of Capecitabine indicated that the developed method is specific for the estimation of Capecitabine. Further the proposed RP-HPLC method has excellent sensitivity, precision and reproducibility.

### REFERENCE

1. McMurry, John (2011). Organic chemistry: with biological applications(2nd ed.). Belmont, CA: Brooks/Cole. p. 395. ISBN 9780495391470.
2. Hostettmann, K; Marston, A; Hostettmann, M (1998). Preparative Chromatography Techniques Applications in Natural Product Isolation(Second ed.). Berlin, Heidelberg: Springer Berlin Heidelberg. p. 50. ISBN 9783662036310
3. <https://www.knauer.net/en/Systems-Solutions/Analytical-HPLC-UHPLC/HPLC-Basics---principles>
4. Rogatsky E. Modern high performance liquid chromatography and HPLC 2016 International Symposium. J Chromatogr Sep Tech. 2016;7:e135.

5. Mulubwa M, et al. Development and validation of high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method for determination of tenofovir in small volumes of human plasma. *J Chromatogr Sep Tech.* 2015;6:300.
6. Santini DA, et al. Development of a high performance liquid chromatography method for the determination of tedizolid in human plasma, human serum, saline and mouse plasma. *J Chromatogr Sep Tech.* 2015;6:270.
7. Lin G, et al. Determination of sodium tanshinone iia sulfonate in rat plasma by high performance liquid chromatography and its application to pharmacokinetics studies. *Pharm Anal Acta.* 2015;6:383.
8. AL-Jammal MKH, et al. Development and validation of micro emulsion high performance liquid chromatography(MELC) method for the determination of nifedipine in pharmaceutical preparation. *Pharm Anal Acta.* 2015;6:347.
9. Myron P, et al. Tributylamine facilitated separations of fucosylated chondroitin sulfate (fucs) by high performance liquid chromatography (HPLC) into its component using 1-phenyl- 3-methyl-5-pyrazolone (pmp) derivatization. *J Chromatogr Sep Tech.* 2015;6:256.
10. Tang M, et al. HPLC analysis of monomer release from conventionally and high temperature high-pressure polymerised urethane dimethacrylate intended for biomedical applications. *J Chromatograph Separat Techniq.* 2014;5:227.